(Q33339149)

English

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A du Bois

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

H J Lück

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

J Pfisterer

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

W Schroeder

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

J U Blohmer

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

R Kimmig

6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

V Moebus

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

J Quaas

8

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 August 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1115-1120

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin plus VP16-213 in refractory ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Letter: Creatinine clearance: bedside estimate.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011605008922

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1011605008922

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33339149&oldid=1568155557"